Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 85, Issue 1, 1998, Pages 78-86

  Katz Levy, Yael ^a   Dayan, Molly ^a   Wirguin, Itzhak ^b   Fridkin, Mati ^a   Sela, Michael ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Acetylcholine receptor; Altered peptide ligands; Myasthenia gravis; T cell inhibition

Indexed keywords

CHOLINERGIC RECEPTOR; RECEPTOR SUBUNIT;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; CELL DIVISION; CELL LINE; CYTOKINES; FEMALE; HUMANS; LYMPH NODES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; PEPTIDE FRAGMENTS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 0032077891     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00265-8     Document Type: Article

References (40)

1. Axelrod O., Mozes E. Analysis of the biological functions and fine specificity of (T,G)-A - L specific T cell clones. Immunobiology. 172:1986;99-109.
2. Berman P.W., Patric J. Experimental myathenia gravis - a murine system. J. Exp. Med. 151:1980;204-210.
3. Brocke S., Brautbar C., Steinman L., Abramsky O., Rothbard J., Neumann D., Fuchs S., Mozes E. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 82:1988;1894-1900.
4. Brocke S., Dayan M., Rothbard J., Fuchs S., Mozes E. The autoimmune response of different mouse strains to T cell epitopes of the human acetylcholine receptor alpha subunit. Immunology. 69:1990;495-500.
5. de Baets M.H., Einarson B., Lindstrom J.M., Weigle W.O. Lymphocyte activation in experimental autoimmune myasthenia gravis. J. Immunol. 128:1982;2228-2235.
6. de Magistris M.T., Alexander J., Coggeshall M., Altman A., Gaeta F.C., Grey H.M., Sette A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:1992;625-634.
7. Drachman D.B. Myasthenia gravis. N. Eng. J. Med. 330:1994;1797-1810.
8. Gaur A., Boehme S.A., Chalmers D., Crowe P.D., Pahuja A., Ling N., Brocke S., Steinman L., Conlon P.J. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. 74:1997;149-158.
9. Gautam A.M., Glynn P. Competition between foreign and self proteins in antigen presentation: ovalbumin can inhibit activation of myelin basic protein-specific T cells. J. Immunol. 144:1990;1177-1180.
10. Gelfand E.W., Weinberg K., Mazer B.D., Kadlecek T.A., Weiss A. Absence of Zap-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes. J. Exp. Med. 182:1995;1057-1066.
11. J.L.J. Hodges, E.L. Lehmann, 1970. Basic Concepts of Probability and Statistics. Holden-Day, San Francisco.
12. Hohlfeld R., Toyka K.V., Heininger K., Grosse-Wilde H., Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature. 310:1984;244-246.
13. Janeway C.A., Bottomly K. Signals and signs for lymphocyte responses. Cell. 76:1994;275-285.
14. Katz-Levy Y., Kirshner S.L., Sela M., Mozes E. Inhibition of T cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7000-7004.
15. Katz-Levy Y., Paas-Rozner M., Kirshner S.L., Dayan M., Zisman E., Fridkin M., Virgin I., Sela M., Mozes E. A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3200-3205.
16. S.B.H. Kent, L.E. Hood, H. Beilan, S. Meister, T. Geiser, 1984. High yield chemical synthesis of biologically active peptides on an automated peptide synthesizer of novel design. In: U. Ragnarsson (Ed.), Peptides, Almqvist and Wiksell Int., Stockholm, pp. 185-188.
17. Kirshner S.L., Katz-Levy Y., Wirguin Y., Argov Z., Mozes E. Fine specificity of T cell line and clones that are capable of inducing autoimmune manifestations in mice. Cell. Immunol. 157:1994;11-28.
18. Krolick K.A., Urso O.E. Influence of T cell specificity on the antibody response to the acetylcholine receptor. J. Neuroimmunol. 13:1986;75-87.
19. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
20. Lindstrom J., Shelton D., Fuji Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-284.
21. Madrenas J., Wange R.L., Wang J.L., Isakov N., Samelson L.E., Germail R.N. Phosphorylation without Zap-70 activation induced by TCR antagonists or partial agonists. Science. 267:1995;515-518.
22. McRae B.L., Nikcevich K.M., Karpus W.J., Hurst S.D., Miller S.D. Differential recognition of peptide analogs by naive versus activated PLP139-151-specific CD4+ T cells. J. Neuroimmunol. 60:1995;17-28.
23. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of EAE in SJL/J mouse. J. Exp. Med. 182:1995;225-244.
24. Mozes E., Dayan M., Zisman E., Brocke S., Licht A., Pecht I. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J. 8:1989;4049-4052.
25. Pia-Protti M., Manfredi A.A., Straub C., Howard J.J., Conti T.B. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc. Natl. Acad. Sci. U.S.A. 87:1990;7792-7796.
26. Racioppi L., Ronchese F., Matis L.A., Germain R.N. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signalling. J. Exp. Med. 177:1993;1047-1060.
27. Sakai K., Zamvil S.S., Mitchell D.J., Hodgkinson S., Rothbard J.B., Steinman L. Prevention of experimental encephalomeyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc. Natl. Acad. Sci. U.S.A. 86:1989;9470-9474.
28. Schnolzer M., Alewood P.F., Kent S.B.H. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40:1992;180-193.
29. Sette A., Alexander J., Ruppert J., Snoke K., Franco A., Ishioka G., Grey H.M. Antigen analog/MHC complexes as specific T cell receptor antagonist. Annu. Rev. Immunol. 12:1994;413-431.
30. Sloan-Lancaster J., Allen P.M. Significance of T cell stimulation by altered peptide ligands in T cell biology. Curr. Opin. Immunol. 7:1995;103-109.
31. Sloan-Lancaster J., Evavold B.D., Allen P.M. Induction of T cell anergy by altered T cell receptor ligand on live antigen-presenting cells. Nature. 363:1993;156-159.
32. Sloan-Lancaster J., Shaw A.S., Rothbard J.B., Allen P.M. Partial T cell signaling: altered phospho-ζ and lack of Zap-70 recruitment in APL-induced T cell anergy. Cell. 79:1994;913-922.
33. Smilek D.E., Wraith D.C., Hodgkinson S., Dwivedy S., Steinman L., McDevitt H.O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 88:1991;9633-9637.
34. Teitelbaum D., Aharoni R., Arnon R., Sela M. Specific inhibition of the T cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9724-9728.
35. Waisman A., Mozes E. Variable region sequences of autoantibodies from mice with experimental systemic lupus erythematosus. Eur. J. Immunol. 23:1993;1566-1573.
36. Waisman A., Ruiz P.J., Eilat E., Konen-Waisman S., Zinger H., Dayan M., Mozes E. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 94:1997;4620-4625.
37. Wauben M.H.M., Boog C.J.P., van der Zee R., Joosten I., Schlief A., van Eden W. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176:1992;667-677.
38. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 324:1986;258-261.
39. Zisman E., Katz-Levy Y., Dayan M., Kirshner S.L., Paas-Rozner M., Karni A., Abramsky O., Brautbar H., Fridkin M., Sela M., Mozes E. Peptide analogs to pathogenic epitopes of the human acetylcholine receptor α subunit as potential modulators of myasthenia gravis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4492-4497.
40. Zisman E., Mozes E. Processing requirements of two acetylcholine receptor derived peptides for binding to antigen presenting cells and stimulation of murine T cell lines. Int. Immunol. 6:1994;683-691.